Measuring and evaluating interferon βs-induced antibodies in patients with multiple sclerosis

Multiple Sclerosis

Volumn 12, Issue 1, 2006, Pages 39-46

  Ross, C ^a   Clemmesen, K M ^a   Sorensen P S ^a   Koch Henriksen, N ^b   Bendtzen, Klaus ^a  

^a Rigshospitalet   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Binding antibodies; Clinical validation; Multiple sclerosis; Neutralizing antibodies; Radioimmunoassay; Screening methods; Therapeutic use; Type 1 interferon

Indexed keywords

BETA INTERFERON; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; PROTEIN G;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; ENZYME IMMUNOASSAY; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PROTEIN PURIFICATION; RADIOIMMUNOASSAY; RELAPSE; REMISSION; SEROLOGY; VALIDATION PROCESS;

ANTIBODIES; ANTIBODY FORMATION; CYTOKINES; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUTRALIZATION TESTS; RADIOIMMUNOASSAY;

EID: 31644438194     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458506ms1272oa     Document Type: Article

References (24)

1. Vilcek J, Feldmann M. Historical review: Cytokines as therapeutics and targets of therapeutics. Trends Pharmacol Sci 2004; 25: 201-209.
2. Antonelli G, Currenti M, Turriziani O, Dianzani F. Neutralizing antibodies to interferon-a: Relative frequency in patients treated with different interferon preparations. J Infect Dis 1991; 163: 882-85.
3. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon b4b: experience during the first three years. Neurology 1996; 47: 889-94.
4. Abdul-Ahad A, Shah S, Galazka A. Incidence of antibodies to interferon-b in patients treated with recombinant human interferon-b1a from mammalian cells. Cytokines Cell Mol Ther 1997; 3: 27-32.
5. Antonelli G, Bagnato F, Pozzilli C, Simeoni E, Bastianelli S, Currenti M et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFNb1a. J Interferon Cytokine Res 1998; 18: 345-50.
6. Sørensen PS, Ross C, Clemmesen EM, Bendtzen K, Frederiksen JL, Jensen K et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-91.
7. Files JG, Gray JL, Do LT, Foley WP, Gabe JD, Nestaas E et al. A novel sensitive and selective bioassay for human type I interferons. J Interferon Cytokine Res 1998; 18: 1019-24.
8. Pungor E, Jr, Files JG, Gabe JD, Do LT, Foley WP, Gray JL et al. A novel bioassay for the determination of neutralizing antibodies to IFN-betalb. J Interferon Cytokine Res 1998; 18: 1025-30.
9. Brickelmaier M, Hochman PS, Baciu R, Chao B, Cuervo JH, Whitty A. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta. J Immunol Methods 1999; 227: 121-35.
10. Grossberg SE, Kawade Y, Kohase M, Klein JP. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res 2001; 21: 729-42.
11. Grossberg SE, Kawade Y, Kohase M, Klein JP. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 2001; 21: 743-55.
12. Kawade Y. An analysis of neutralization reaction of interferon by antibody: a proposal on the expression of neutralization titre. J Interferon Res 1980; 1: 61-70.
13. Bendtzen K. Anti-IFN BAb and NAb antibodies: A minireview. Neurology 2003; 61(Suppl. 5): S6-S10.
14. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double- blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
15. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon b-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85.
16. Kivisäkk P, Alm GV, Tian WZ, Matusevicius D, Fredrikson S, Link H. Neutralising and binding anti-interferon-b-1 b (IFN-b-lb) antibodies during IFN-b-1b treatment of multiple sclerosis. Mult Scler 1997; 3: 184-90.
17. Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998; 50: 1266-72.
18. Ross C, Clemmesen KM, Svenson M, Sørensen PS, Koch-Henriksen N, Skovgaard GL et al. Immunogenicity of interferon-b in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurology 2000; 48: 706-12.
19. Bendtzen K, Ross C, Hansen MB, Svenson M. Natural and induced anti-cytokine antibodies. In Ciliberto G, Savino R, eds. Cytokine Inhibitors. New York: Marcel Dekker, 2000: 53-95.
20. Ross C, Engler CB, Sander B, Bendtzen K. IFN-a antibodies in patients with age-related macular degeneration treated with recombinant human IFN-a2a. J Interferon Cytokine Res 2002; 22: 421-26.
21. Bendtzen K, Hansen MB, Ross C, Svenson M. Detection of autoantibodies to cytokines. Mol Biotechnol 2000; 14: 251-61.
22. Giovannoni G, Munschauser FE 3rd, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg PS 2002; 73: 465-9.
23. Pachner AR. An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients. Neurology 2003; 61: 1444-46.
24. Giovannoni G. Strategies to treat and prevent the development of neutralizing anti-interferon-b antibodies. Neurology 2003; 61(Suppl. 5): S13-17.